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Osteogenesis Imperfecta (OI) is a rare autosomal dominant connective tissue disorder in wich, the bone quality and 
density is affected. OI includes some metabolic disorders and have a wide range of clinical presentations. In Osteo-
genesis Imperfecta bone has a very low density and it is a disorder currently treated with bisphosphonates. Quality 
and quantity of bone is important for establishment of osseointegration in dental implants. There are few reported 
cases in the literature. This is a case report of a 61 year-old man with grade IV OI, rehabilitated with implant-
supported fixed prostheses in the posterior right and left mandible, whithout bone grafts. At the 4-year follow-up, 
clinical and imaging study showed no evidence of pathology in the peri-implant tissues. The final outcome is a 
correct occlusion and masticatory function. This case shows that dental implants may be a treatment option in this 
patients, however there is still quite limited scientific evidence.





Osteogenesis Imperfecta (OI) is a connective tissue he-
reditary disorder which comprises a broad spectrum of 
phenotypic presentations. It is a heterogeneous genetic 
disorder which affects mainly type 1 collagen (1). OI 
clinical management is multidisciplinary and it reaches 
from physical rehabilitation and surgical procedures, au-
dition management, dental and lung disorder as well as 
the use of bisphosphonates (BP).
Glorieux et al. in 1998, suggested using the BP therapy 
for OI patients. Their treatment was very limited to small 
groups of patients (2). Although different clinical uses of 
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BP have been reported since 1990 (3), it is in 1995 when 
the first case of the fail of osseointegration in implant 
surgery in a patient undergoing BP therapy for Osteopo-
rosis treatment was published (4). It was in 2001 when 
secondary effects of BP were mostly reported, as at this 
moment their use became very popular and osseous di-
sorders were diagnosed in patients undergoing this kind 
of treatment (3-5), already  in 2003 definitive diagnosis 
of Maxillary Osseous Necrosis related to  BP was esta-
blished (4), because of this, identifying patients under 
risk has become very important for health professionals, 
pharmacy industry and health regulating organizations 
to avoid the development of mentioned complications 
(4,5).
Most of the affected patients were the ones who un-
derwent some kind or invasive dental treatment and un-
der intravenous (IV) BP therapy, as zoledronic acid and 
pamidronate. In 2006 Maxillary Osseous Necrosis was 
reported secondary to the use of oral bisphosphonates as 
Alendronate (4). 
Recent data indicate a prevalence of Maxillary Osteo-
necrosis Induced by Bisphosphonates (MOIB) of 1 to 
5% with intravenous bisphosphonates therapy, and from 
0.001 to 0.01% with oral bisphosphonates, as well as 
from 0.09 to 0.34% after an invasive dental treatment 
(3). It has been found that the most affected structures 
are the mandible in a 78%, the maxilla 16% and both can 
be affected in a 5%; in 52% it occurred in patients who 
underwent a dental extraction and in 48% spontaneously 
(3-6).
It is known that treatment with intravenous via BP will 
enhance toxicity and susceptibility to develop a MOIB, 
on the other hand, when medication is administered ora-
lly the risk will be related to the ingested dose and the 
exposition time. There will be more risk as the duration 
of the treatment is longer; each decade of treatment will 
increase in a 9% the risk for the patient (5).
Patients receiving  BP intravenous therapy and also un-
dergoing some kind of maxillary surgery, have 7 times 
more risk to develop MOIB than those who do not under-
go any procedure (5). The uncertainty in their treatment 
which the professional must face is due to the possible 
mandibular osteonecrosis, to the difficulty in soft tissues 
cicatrization and the potential lack of implant osseoin-
tegration due to the low density of bone in this type of 
patients.
Long term results are unpredictable (7). We have not 
found in the literature any protocol to prepare the im-
plant site in patients with Osteogenesis Imperfecta. The 
aim of this work is to describe the protocol used to insert 
implants in a patient with OI treated with intravenous 
bisphosphonates, the rehabilitation with partial  implant-
supported prosthetics and its favorable evolution-without 
complications- in 4 years.
Case Report
The case involves a 61 year old, male patient, who 
arrived in the dental clinic because he was not able to 
chew properly due to his removable prosthesis. The pa-
tient, with grade IV Osteogenesis Imperfecta, desired to 
have a better situation possibly replacing his removable 
prostheses for a fixed option. The patient is smoker, 20 
cigarettes a day, with previous stroke/cerebrovascular 
accident (CVA) in 2007, head of the femur prostheses 
in 2009, and multiple fractures in his legs. His OI was 
treated with Aclasta® 5 mg. (zoledronic acid) in solution 
for intravenous perfusion every six months since 2011. 
Last dose in June 2015, his physician suspended the 
treatment. Adiro® 300 mg. (acetylsalicylic acid) tablets 
every 24 hours since 2007 until nowadays and Hidrofe-
rol® vials 1.5 ml (calcifediol) every 15 days since 2009 
until nowadays. Intraoral clinical exam: He presents par-
tial edentulism, residual dental roots in third quadrant, 
cervical caries in 16 with severe mobility, poor oral hy-
giene, upper removable partial prosthesis. Radiographic 
Exam: Orthopantomography (OPG):  root fragments in 
36 area, caries with pulp involvement in 16, cervical 
caries in 13. Dental absence in the anterior area of the 
second quadrant  and molar area of first, second, third 
and fourth quadrant. Cone Beam Computed Tomogra-
phy (CBCT) : Very low density bone is observed in the 
upper maxilla, 158 Hounsfield Units (HU) osseous den-
sity in cancellous bone, 670 HU in cortical bone. And 
in the lower jaw, 78 HU osseous density in cancellous 
bone, 443 HU in cortical bone (Fig. 1).
After evaluating the risks, we decide with the patient, to 
accomplish the following treatment plan: Oral hygiene 
instructions, elimination of local factors, tobacco, bac-
terial plaque and caries, root fragments of 36 extraction, 
extraction of 16, partial fixed prosthesis in the upper 
jaw with metal-ceramic crowns with attachments in 13-
12-11-21, Removable Partial upper posterior prosthesis 
with attachments, Partial Fixed Lower Prosthesis with 
metal-ceramic crowns from 34 to 45, Implant supported 
prosthesis on implants C1 (sand-blasted and acid-echted 
surface, conical shaped, conical connection and platform 
switching) of MIS Implants Technologies LTD, Shlomi, 
Israel, two implants area 36-35 (MIS C1 3.75x10), one 
in 46 (MIS C1 3.75 X 11.5), MIS Multiunit abutments 
in third quadrant, MIS transepithelial abutment. Design 
for cement-screwed crown in 46, Crowns on implants 
36-35 and 46. The patient signed two specific informed 
consent, one for the dental extractions and the second 
one for the implant insertion. 
Objective of the treatment: Functional reestablishment 
of the patient dentition by an oral rehabilitation formed 
by a fixed implant-supported prosthesis in the lower mo-
lar area and dental-supported in the upper.
Dental extractions: Were performed under antibiotic 
prophylaxis of amoxicillin 500 mg. capsules every 8 
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Fig. 1: CBCT (a) Bone density in cancellous bone. (b) Planning implant 46. Bicortical an-
chorage. (c) Planning implant 36. Bicortical anchorage.
hours since one day before dental extraction and until 6 
days after. In October 2011were extracted the radicular 
rests of the left mandibular first molar-36 (four month 
after the last BP dose)and in april2012 was extracted the 
right maxillary first molar-16 (four month after the last 
BP dose).
Description of the technique of low density bone drilling 
in OI: 
Treatment is started 2 months after the last dose of bis-
phosphonates, with an antibiotic prophylaxis of amoxi-
cillin 500 mg. capsules every 8 hours since one day 
before implant placement and until 6 days after. The 
adjacent mucosa was dried  followed by application of 
topical anesthetic gel (benzocaine 2%) with the help of 
cotton applicator for about 30 s. Later, 1.8 ml of anesthe-
tic solution (2% lidocaine with epinefrine 1:50,000 buc-
cally [0.9 ml] and lingually [0.9 ml], was injected under 
aseptic conditions using a European thread M6x0,75 
(0,3x25mm) gauge needle at a rate of approximately 1 
ml/min. To achieve effective buccal and lingual anes-
thesia, the procedure was delayed for at least 5 min. The 
plan is to get a bicortical anchorage, the implant will not 
act as a compactor, a protocol of drilling with the com-
plete sequence and new drills at low speed is followed 
(120 RPM), plenty of irrigation with sterile physiologi-
cal saline solution, Three C1 implants were placed sub-
crestal (submerged), taking place in two surgical times, 
leaving 6 months between these two phases to allow os-
seointegration.
Primary anchorage in the lingual cortical and in the cor-
tical apical to the implant (mylohyoid line) was aimed 
at the moment of the implant placement. The cancellous 
bone presents very low density.
Implants at third and fourth quadrant were placed in di-
fferent times. The aim was to check if the healing pro-
cess was favorable, due to the risk of osteonecrosis. MIS 
C1 Implant on area 46 of 3.75x11.5 and insertion torque 
of 50 Ncm was placed in August 2012 (two month after 
the last BP dose). Once the correct healing of the soft 
tissues was checked and after observing the osseointe-
gration on the x-rays, two MIS C1 implants of 3.75x10 
with a programmed torque of 50 Ncm,  were placed on 
area 36 and 37 in November 2012 (five month after the 
last BP dose), and one month after the implant insertion 
the zolendronic acid treatment was restarted by his phy-
sician. Prosthetic Rehabilitation: Placement of healing 
abutments, checking implant stability, taking impres-
sions, trying on the structure, trying the ceramic, occlu-
sion adjustment, placement of crowns on implants in 
September 2013 with a torque of 35 Ncm, control after a 
month (8-10) (Fig. 2).
Recommended Maintenance: Oral hygiene instructions 
were explained. Daily use of a water jet. Daily use of 
a mouth rinsing solution of Chlorhexidine Diglucona-
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Fig. 2: Radiographic and soft-tissue controls. (a) OPG with placement dates of implants. (b) 
Integrated bone implants are seen. Exploration for the placement of healing abutments. (c) 
Healthy soft tissues with healing abutments.
te 0.12%. Soft diet. Monitoring and professional dental 
cleaning every six months.
Clinical and radiological examinations were performed 
in order to follow up the case. Stability of the peri-im-
plant tissues is found at the follow-up visits, the patient 
is very happy with the results, he refers to have a very 
diverse diet and keeps on smoking. The existing kerati-
nized gum is stable, although insufficient at implant on 
area of 36. Oral hygiene is deficient. On January 2014 
follow up, a slight bone loss at the crestal area of implant 
on 36 area starts to be noticeable, generalized gingival 
inflammation is observed, in every teeh, related to the 
presence of bacterial plaque, it is observed that peri-im-
plant tissues are in good health. In later follow-ups until 
July 2016 peri-implant tissues are stable, with a loss of 
1.25mm of crestal bone on the area of implant 36, the 
same level that was measured in 2014 (Fig. 3).
Discussion
Treatment with dental implants in patients with OI is ex-
tremely rare. We have been able to find only six cases 
previously published in the scientific literature (7,8,11-
14). The intravenous (IV) administration of bisphos-
phonates implies a special situation, which relevance is 
associated to the time of exposure of the patient to this 
drug therapy, under or over 3 years and if he is exposed 
to OMIB associated risk factors, smoking, bad oral hy-
giene, periodontal disease (5).
Implant insertion in maxillary bones on patients under-
going OI and who are treated with IV bisphosphonates 
is considered by some authors an unfeasible treatment 
(15). However we need to know the dose of IV BF, the 
zolendronic acid used in the treatment of the patient in 
OI is 5 mg every 6 months (Aclasta®), and in patients 
with bone-metastases is 4 mg every 3 to 4 weeks. This 
difference of dose and dosage regimen can explain the 
risks and benefits of continuing bisphosphonate thera-
py and justify the treatment decision made individually 
with the patient (5). 
With these reported cases, a great possibility opens for 
future patients with this pathology, they will be able to be 
rehabilitated with fixed prosthesis on implants although 
it is necessary to develop more studies and to scientifica-
lly check its feasibility.
It is very important that both dentists as every health-
care professional can manage the basic principles for 
preventing osteonecrosis caused by bisphosphonates, by 
the acomplishment of precise medical records and es-
tablishing a multidisciplinary  management in patients 
susceptible to develop this illness, in such a way that 
wrong, misinterpreted or late diagnosis and, at the end, 
failed treatments that could worsen the course of this 
condition will be avoided (15).
Conclusions
This case shows that dental implants may be a treatment 
option in patients with osteogenesis imperfecta, howe-
ver there is still a limited scientific evidence and special 
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Fig. 3: Radiographic control dated July 28, 2016. (a) OPG with fixed prosthesis (b) Reha-
bilitation implant zone 46. (c) 36-37 Implants zone. 1.25 mm of bone loss is observed in the 
implant 36.
attention must be focused to the potential risks of the in-
travenous bisphosphonates therapy and the patient must 
know that it is an individual case.
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